Phase 1/2CompletedAge-related condition
Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV) (Disc_allo)
Treatment of Lumbar Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV*) *MSV: Bone Marrow Mesenchymal Stromal Cells Expanded Using the Valladolid IBGM Procedure
- Sponsor
- Red de Terapia Celular (Industry)
- Enrollment
- 24 enrolled
- Conditions
- Degenerative Disc Disease; Intervertebral Disc Disease; Low Back Pain
- Interventions
- Allogenic Mesenchymal Stromal Cells; Mepivacaine
- Ages
- adults, older adults
- Registry
- NCT01860417, EUCTR2012-004444-30
Full record on ClinicalTrials.gov
From the registry
In this study we want to evaluate the clinical use of allogenic mesenchymal stem cells (MSC), obtained from bone marrow of healthy donors, for treatment of Degenerative Disc Disease (DDD). The trial is based in previous results with autologous MSC (Orozco et al., Transplantation 92: 822-828; 2011). Here we propose a phase I-II trial, prospective, randomized, blinded, and controlled for the treatment DDD using MSV, a Good Manufacturing Practice (GMP)-compliant expanded bone marrow MSC (MSV, Investigational medicinal product Num. 10-134). The assay consists of two arms with 12 patients each one. Patients in the experimental arm will be given a single intra-discal transplantation of MSV (25 millions in 2 ml). Control patients will be infiltrated in the paravertebral muscles close to the lesion with 2 ml of 1% mepivacain. We shall follow the evolution of pain, disability and quality of life as well as disc fluid content by Magnetic Resonance Imaging (T2-calibrated).
Primary outcomes
- Pain and Disability Evaluation
History
Results first posted
Last registry update
Primary completion
Started
Registered